Genentech, Inc.
NEWS
It was a particularly busy week for clinical trial announcements. Let’s take a look.
Interim data from Genentech’s first randomized study on a candidate treatment for extensive-stage small-cell lung cancer failed to meet its co-primary endpoint.
The study suggests that artificial sweeteners, which are readily available in coffee shops and used in diet soft drinks, increase the risks of breast cancer and obesity.
A federal judge in Delaware tossed out a lawsuit by Genentech, Inc., a Roche company, accusing Novartis’ Sandoz division of patent infringement.
It was a busy week for clinical trial announcements. Here’s a look.
A closer look at legal action against executives from the company formerly known as JHL Biotech who recruited scientists from Genentech to steal trade secrets related to several cancer drugs.
Genentech shared new data from its SUNFISH study evaluating the use of Evrysdi for SMA people ages 2 to 25 years diagnosed with Type 2 or Type 3 spinal muscular atrophy.
Two former executives of JHL Biotech were sentenced to a year and one day each in prison after being found guilty of conspiracy and fraud.
Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.
JOBS
IN THE PRESS